Published on Jun 18, 2019
Prof Jorge Garcia speaks to ecancer at the 2019 International Gastrointestinal, Liver and Uro-Oncology Conference (IGILUC) in Cairo about the various treatment options available for locally advanced renal cell carcinoma (RCC) patients in both the first-line and second-line setting.
Prof Garcia describes the historic use of targeted therapies such as tyrosine kinase and vascular endothelial growth factor inhibitors as the standard front-line choice of therapy for these patients.
For the second-line setting, he also states two agents (cabozantinib and nivolumab) which have both demonstrated a survival benefit for advanced RCC patients.
Over the last 18 months, Prof Garcia notes the utilisation of immuno-oncology agents in patients with untreated RCC during the front-line setting. In particular the use of the ipilimumab plus nivolumab regimen, which has become the standard of care in men with untreated, clear cell, metastatic RCC. However, this may change with encouraging data supporting the use of the pembrolizumab/axitinib regimen.
Prof Garcia concludes by stating the challenges clinicians face in the treatment of RCC, which include the absence of an effective biomarker which leads to the reliance of obsolete clinical features.